These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 31456796)

  • 1. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
    Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
    Front Immunol; 2019; 10():1782. PubMed ID: 31456796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.
    Gonzalez VD; Huang YW; Delgado-Gonzalez A; Chen SY; Donoso K; Sachs K; Gentles AJ; Allard GM; Kolahi KS; Howitt BE; Porpiglia E; Fantl WJ
    Cell Rep; 2021 Aug; 36(9):109632. PubMed ID: 34469729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer treatment and natural killer cell-based immunotherapy.
    Fan Z; Han D; Fan X; Zhao L
    Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.
    Pugh-Toole M; Nicolela AP; Nersesian S; Leung BM; Boudreau JE
    Curr Treat Options Oncol; 2022 Feb; 23(2):210-226. PubMed ID: 35192139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
    Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
    Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the immune microenvironment for ovarian cancer therapy.
    Blanc-Durand F; Clemence Wei Xian L; Tan DSP
    Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem-cell based, machine learning approach for optimizing natural killer cell-based personalized immunotherapy for high-grade ovarian cancer.
    Esmail S; Danter WR
    FEBS J; 2022 Feb; 289(4):985-998. PubMed ID: 34582617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
    Pasero C; Gravis G; Guerin M; Granjeaud S; Thomassin-Piana J; Rocchi P; Paciencia-Gros M; Poizat F; Bentobji M; Azario-Cheillan F; Walz J; Salem N; Brunelle S; Moretta A; Olive D
    Cancer Res; 2016 Apr; 76(8):2153-65. PubMed ID: 27197252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
    Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
    Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK Cells in the Tumor Microenvironment.
    Guillerey C
    Adv Exp Med Biol; 2020; 1273():69-90. PubMed ID: 33119876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.